• Something wrong with this record ?

Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests

J. Lyytikäinen, S. Kyllönen, T. Ervasti, E. Komulainen, T. Pekarek, J. Slunečková, J. Leskinen, J. Ketolainen, T. Kubelka, P. Stasiak, O. Korhonen

. 2023 ; 647 (-) : 123509. [pub] 20231011

Language English Country Netherlands

Document type Journal Article

As is the case with batch-based tableting processes, continuous tablet manufacturing can be conducted by direct compression or with a granulation step such as dry or wet granulation included in the production procedure. In this work, continuous manufacturing tests were performed with a commercial tablet formulation, while maintaining its original material composition. Challenges were encountered with the feeding performance of the API during initial tests which required designing different powder pre-blend compositions. After the pre-blend optimization phase, granules were prepared with a roller compactor. Tableting was conducted with the granules and an additional brief continuous direct compression run was completed with some ungranulated mixture. The tablets were assessed with off-line tests, applying the quality requirements demanded for the batch-manufactured product. Chemical maps were obtained by Raman mapping and elemental maps by scanning electron microscopy with energy-dispersive X-ray spectroscopy. Large variations in both tablet weights and breaking forces were observed in all tested samples, resulting in significant quality complications. It was suspected that the API tended to adhere to the process equipment, accounting for the low API content in the powder mixture and tablets. These results suggest that this API or the tablet composition was unsuitable for manufacturing in a continuous line; further testing could be continued with different materials and changes in the process.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000614
003      
CZ-PrNML
005      
20240213093303.0
007      
ta
008      
240109e20231011ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2023.123509 $2 doi
035    __
$a (PubMed)37832703
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Lyytikäinen, Jenna $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jenna.lyytikainen@uef.fi
245    10
$a Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests / $c J. Lyytikäinen, S. Kyllönen, T. Ervasti, E. Komulainen, T. Pekarek, J. Slunečková, J. Leskinen, J. Ketolainen, T. Kubelka, P. Stasiak, O. Korhonen
520    9_
$a As is the case with batch-based tableting processes, continuous tablet manufacturing can be conducted by direct compression or with a granulation step such as dry or wet granulation included in the production procedure. In this work, continuous manufacturing tests were performed with a commercial tablet formulation, while maintaining its original material composition. Challenges were encountered with the feeding performance of the API during initial tests which required designing different powder pre-blend compositions. After the pre-blend optimization phase, granules were prepared with a roller compactor. Tableting was conducted with the granules and an additional brief continuous direct compression run was completed with some ungranulated mixture. The tablets were assessed with off-line tests, applying the quality requirements demanded for the batch-manufactured product. Chemical maps were obtained by Raman mapping and elemental maps by scanning electron microscopy with energy-dispersive X-ray spectroscopy. Large variations in both tablet weights and breaking forces were observed in all tested samples, resulting in significant quality complications. It was suspected that the API tended to adhere to the process equipment, accounting for the low API content in the powder mixture and tablets. These results suggest that this API or the tablet composition was unsuitable for manufacturing in a continuous line; further testing could be continued with different materials and changes in the process.
650    _2
$a atorvastatin $7 D000069059
650    _2
$a prášky, zásypy, pudry $x chemie $7 D011208
650    _2
$a tablety $x chemie $7 D013607
650    _2
$a tlak $7 D011312
650    _2
$a příprava léků $x metody $7 D004339
650    12
$a farmaceutická technologie $x metody $7 D013678
650    _2
$a velikost částic $7 D010316
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kyllönen, Saini $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: sainik@student.uef.fi
700    1_
$a Ervasti, Tuomas $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: tuomas.ervasti@uef.fi
700    1_
$a Komulainen, Eelis $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: eelis.komulainen@uef.fi
700    1_
$a Pekarek, Tomáš $u Zentiva k.s., Prague, Czech Republic. Electronic address: Tomas.Pekarek@zentiva.com
700    1_
$a Slunečková, Jitka $u Zentiva k.s., Prague, Czech Republic. Electronic address: jitka.sluneckova@zentiva.com
700    1_
$a Leskinen, Jari $u Department of Technical Physics, University of Eastern Finland, Kuopio, Finland. Electronic address: jari.leskinen@uef.fi
700    1_
$a Ketolainen, Jarkko $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jarkko.ketolainen@uef.fi
700    1_
$a Kubelka, Tomáš $u Zentiva k.s., Prague, Czech Republic. Electronic address: Tomas.Kubelka@zentiva.com
700    1_
$a Stasiak, Pawel $u Zentiva k.s., Prague, Czech Republic. Electronic address: pawel.stasiak@zentiva.com
700    1_
$a Korhonen, Ossi $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: ossi.korhonen@uef.fi
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 647 (20231011), s. 123509
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37832703 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093300 $b ABA008
999    __
$a ok $b bmc $g 2049332 $s 1210308
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 647 $c - $d 123509 $e 20231011 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...